Targeting vascular cell migration as a strategy for blocking angiogenesis: the central role of focal adhesion protein tyrosine kinase family.
The formation of capillary-like structures during angiogenesis requires a series of well-orchestrated cellular events allowing endothelial cells and pericytes to migrate into the perivascular space. The proper activation of the migratory machinery in these cells is fine controlled by the presence of angiogenic challenges and by the interactions with extracellular matrix. The two members of the focal adhesion protein tyrosine kinases (FA-PTKs), FAK and PYK2, play a central role in modulating endothelial and vascular smooth muscle cells migration confirming the well consolidated observations in other migrating cell types. However accumulating data reveal that FAK and PYK2 are involved in several cell processes including cell proliferation and survival. FAK, once localized to focal adhesions, is thought to be one of the principal effectors in linking signals initiated by integrins and growth factor receptors to cytoskeleton, thus controlling migration. Although more obscure, and differently regulated, the function of PYK2 seems to be similar to that of FAK, but restricted to few cell types, including vasculature forming cells. FAK and PYK2 exert a primary role as adaptor proteins able to recruit, with high turnover, several proteins which in turn, through their docking domains and tyrosine kinase activity, determine both the turnover in focal adhesion assembly and the specificity of downstream signaling. The characterization of functional interactions of FA-PTKs may provide new potential therapeutic targets in order to control vascular pathological processes including angiogenesis.
Angelucci
A
A
Department of Basic and Applied Biology, University of L'Aquila, L'Aquila, Italy. adriano.angelucci@gmail.co
Bologna
M
M
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D002384:Catalysis; D002465:Cell Movement / Q000187:drug effects; D005109:Extracellular Matrix / Q000502:physiology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D051418:Focal Adhesion Kinase 2 / Q000037:antagonists & inhibitors* / Q000502:physiology; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology; D022001:Focal Adhesions / Q000187:drug effects; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects*; D032389:Myocytes, Smooth Muscle / Q000187:drug effects*; D018919:Neovascularization, Physiologic; D010766:Phosphorylation; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology
D020533:Angiogenesis Inhibitors; D010982:Platelet-Derived Growth Factor; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; D000804:Angiotensin II; D040262:Receptors, Vascular Endothelial Growth Factor; D051418:Focal Adhesion Kinase 2; D051416:Focal Adhesion Protein-Tyrosine Kinases